Balchem: Robust Growth Outlook, Margin Resilience, and Structural Tailwinds Support Buy Rating and $190 Target

H.C. Wainwright analyst Ram Selvaraju has reiterated their bullish stance on BCPC stock, giving a Buy rating on February 21.

Ram Selvaraju has given his Buy rating due to a combination of factors, including Balchem’s solid recent performance and supportive outlook. The company delivered record 2025 revenue very close to expectations and slightly exceeded earnings forecasts, while management’s guidance implies continued growth led by the Human Nutrition and Health segment and steady contributions from animal health and specialty products.

He also points to resilient margins, with gross profit expanding year over year despite higher input costs, and sees European anti-dumping duties on Chinese choline chloride as a structural tailwind for Balchem’s choline-based offerings. In addition, limited exposure to U.S. tariff swings, potential currency benefits from a weaker dollar, and a largely unchanged valuation multiple underpin his maintained $190 price target and support the Buy recommendation.

According to TipRanks, Selvaraju is a 5-star analyst with an average return of 23.3% and a 56.77% success rate. Selvaraju covers the Healthcare sector, focusing on stocks such as Vanda, Idorsia Ltd, and Ultragenyx Pharmaceutical.

In another report released on February 21, TipRanks – Google also reiterated a Buy rating on the stock with a $205.00 price target.